Clinical Trial for Brain Cancer Glioblastoma Immunotherapy SurVaxM
Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy...
Read More
Tag: Robert Fenstermaker MD
Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study
Phase II clinical trial will assess efficacy of Roswell Park-developed immunotherapy in newly diagnosed patients BUFFALO, N.Y. — An innovative vaccine therapy developed at Roswell Park Cancer Institute (RPCI) is being tested in...
Read More
